(SAN) Sanofi - Overview
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: PA (France) | Market Cap: 91.871m EUR | Total Return: 60.1% in 12m
Avg Turnover: 168M
EPS Trend: -65.1%
Qual. Beats: 0
Rev. Trend: 42.4%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Sanofi is a global pharmaceutical company headquartered in France, specializing in the research and development of immunology, oncology, rare diseases, and vaccines. The company maintains a significant presence in the pediatric and travel vaccine markets, producing treatments for polio, pertussis, and various viral infections. Its business model relies heavily on a strategy of external innovation, utilizing numerous collaboration and license agreements with biotechnology firms to expand its pipeline in small-molecule and protein degradation therapies.
The pharmaceutical sector is characterized by high research and development (R&D) intensity and a rigorous regulatory approval process for new drug candidates. Sanofi increasingly integrates artificial intelligence and genome editing technologies into its discovery phase to accelerate clinical timelines. To gain a deeper understanding of these valuation drivers, investors may find it useful to review the detailed financial metrics available on ValueRay.
Recent strategic partnerships include agreements with Teva Pharmaceuticals for inflammatory bowel disease treatments and Scribe Therapeutics for genome editing. The company’s portfolio diversification across multiple therapeutic areas helps mitigate the impact of patent expirations on specific legacy drugs.
- Dupixent sales volume expansion remains the primary driver of organic revenue growth
- Pipeline transition toward immunology and inflammation offsets loss of patent exclusivity
- Increased research and development spending pressures short-term operating margins and profitability
- Strategic separation of consumer healthcare business impacts capital allocation and valuation
- Successful pediatric vaccine launches drive market share gains in core therapeutic categories
| Net Income: 10.4b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 0.87 > 1.0 |
| NWC/Revenue: 0.34% < 20% (prev 26.24%; Δ -25.91% < -1%) |
| CFO/TA 0.16 > 3% & CFO 19.9b > Net Income 10.4b |
| Net Debt (16.3b) to EBITDA (16.7b): 0.98 < 3 |
| Current Ratio: 1.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.20b) vs 12m ago -2.41% < -2% |
| Gross Margin: 64.03% > 18% (prev 0.71%; Δ 6.33k% > 0.5%) |
| Asset Turnover: 35.74% > 50% (prev 34.08%; Δ 1.66% > 0%) |
| Interest Coverage Ratio: 20.69 > 6 (EBITDA TTM 16.7b / Interest Expense TTM 714.0m) |
| A: 0.00 (Total Current Assets 30.2b - Total Current Liabilities 30.0b) / Total Assets 128b |
| B: 0.52 (Retained Earnings 66.9b / Total Assets 128b) |
| C: 0.11 (EBIT TTM 14.8b / Avg Total Assets 130b) |
| D: 1.26 (Book Value of Equity 69.3b / Total Liabilities 54.9b) |
| Altman-Z'' = 3.80 = AA |
| DSRI: 1.04 (Receivables 482.0m/447.0m, Revenue 46.5b/45.0b) |
| GMI: 1.11 (GM 64.03% / 70.93%) |
| AQI: 1.16 (AQ_t 0.67 / AQ_t-1 0.58) |
| SGI: 1.03 (Revenue 46.5b / 45.0b) |
| TATA: -0.07 (NI 10.4b - CFO 19.9b) / TA 128b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of May 29, 2026, the stock is trading at EUR 76.36 with a total of 2,274,060 shares traded.
Over the past week, the price has changed by +0.24%,
over one month by +4.08%,
over three months by +1.64% and
over the past year by +60.12%.
Sanofi has no consensus analysts rating.
P/E Trailing = 19.4141
P/E Forward = 8.8889
P/S = 1.9401
P/B = 1.2618
P/EG = 3.8643
Revenue TTM = 46.5b EUR
EBIT TTM = 14.8b EUR
EBITDA TTM = 16.7b EUR
Long Term Debt = 12.3b EUR (from longTermDebt, last quarter)
Short Term Debt = 6.18b EUR (from shortTermDebt, last quarter)
Debt = 21.8b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.80b
Net Debt = 16.3b EUR (calculated: Debt 21.8b - CCE 5.54b)
Enterprise Value = 108b EUR (91.9b + Debt 21.8b - CCE 5.54b)
Interest Coverage Ratio = 20.69 (Ebit TTM 14.8b / Interest Expense TTM 714.0m)
EV/FCF = 6.83x (Enterprise Value 108b / FCF TTM 15.8b)
FCF Yield = 14.65% (FCF TTM 15.8b / Enterprise Value 108b)
FCF Margin = 34.10% (FCF TTM 15.8b / Revenue TTM 46.5b)
Net Margin = 22.30% (Net Income TTM 10.4b / Revenue TTM 46.5b)
Gross Margin = 64.03% ((Revenue TTM 46.5b - Cost of Revenue TTM 16.7b) / Revenue TTM)
Gross Margin QoQ = 72.09% (prev 36.58%)
Tobins Q-Ratio = 0.84 (Enterprise Value 108b / Total Assets 128b)
Interest Expense / Debt = 3.27% (Interest Expense 714.0m / Debt 21.8b)
Taxrate = 20.85% (420.0m / 2.01b)
NOPAT = 11.7b (EBIT 14.8b * (1 - 20.85%))
Current Ratio = 1.01 (Total Current Assets 30.2b / Total Current Liabilities 30.0b)
Debt / Equity = 0.30 (Debt 21.8b / totalStockholderEquity, last quarter 72.8b)
Debt / EBITDA = 0.98 (Net Debt 16.3b / EBITDA 16.7b)
Debt / FCF = 1.03 (Net Debt 16.3b / FCF TTM 15.8b)
Total Stockholder Equity = 71.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.97% (Net Income 10.4b / Total Assets 128b)
RoE = 14.41% (Net Income TTM 10.4b / Total Stockholder Equity 71.9b)
RoCE = 17.55% (EBIT 14.8b / Capital Employed (Equity 71.9b + L.T.Debt 12.3b))
RoIC = 11.22% (NOPAT 11.7b / Invested Capital 104b)
WACC = 5.81% (E(91.9b)/V(114b) * Re(6.57%) + D(21.8b)/V(114b) * Rd(3.27%) * (1-Tc(0.21)))
Discount Rate = 6.57% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -65.93 | Cagr: -1.77%
[DCF] Terminal Value 76.00% ; FCFF base≈15.6b ; Y1≈16.2b ; Y5≈18.4b
[DCF] Fair Price = 224.7 (EV 285b - Net Debt 16.3b = Equity 269b / Shares 1.19b; r=8.35% [WACC [floored]]; 5y FCF grow 4.40% → 2.50% )
EPS Correlation: -65.15 | EPS CAGR: -2.47% | SUE: 0.59 | # QB: 0
Revenue Correlation: 42.40 | Revenue CAGR: 2.94% | SUE: 1.19 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.86 | Chg30d=-0.53% | Revisions=+14% | Analysts=6
EPS next Quarter (2026-09-30): EPS=3.02 | Chg30d=-4.51% | Revisions=-14% | Analysts=6
EPS current Year (2026-12-31): EPS=8.50 | Chg30d=-0.30% | Revisions=+22% | GrowthEPS=+8.6% | GrowthRev=+7.9%
EPS next Year (2027-12-31): EPS=9.00 | Chg30d=-0.86% | Revisions=+18% | GrowthEPS=+5.9% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: +22%